The National Association of Dental Laboratories will host a free webinar, "COVID-19 Safety and Infection Protection Guidance for Dental Laboratories," presented by Mary A. Bartlett and Gary D. Morgan, on April 1 from 2-3 PM.
Bartlett and Morgan, both of Safelink Consulting, Inc., will review the COVID-19 safety concerns that they have been addressing with their dental laboratory clients over the past several weeks. The course will allow ample time for questions and answers.
The webinar has been approved for 1 hour of Regulatory Standards CE credit through the National Board for Certification (NBC). Due to the potential high demand and limited space within the webinar platform, only the first 500 registrants will be able to attend the live version of the webinar. However, the NADL will make a recording available at no charge approximately 2 to 3 days after the webinar.
To register, click here.
The National Association of Dental Laboratories (NADL) issued guidance on key provisions for dental laboratories in the CARES Act, which recently passed in the Senate.
These include provisions involving Small Business Administration (SBA) loans, withdrawal of money from retirement funds, federal student loan payments, employer shares of Social Security tax, emergency unemployment compensation benefits, and more.
For the full report from the NADL, click here.
In response to COVID-19, Carbon will digitally host a free online chat between dental laboratory thought-leaders to help dental laboratory professionals navigate through the uncertainty of these unprecedented times.
The webinar will be Tuesday, March 31 from 12-1 PM. Attendees will learn about resources available to small businesses, suggestions on how to handle your team, short- and medium-term plans to survive in this turbulent environment, and strategies to ramp up production to meet customer needs once this crisis ends. Carbon's David Moehlman will moderate a discussion with Megan Nakanishi, Conrad Rensburg, and Ashley Byrne.
To register, click here.
Ivoclar Vivadent is shifting its International Expert Symposium 2020 on 12th and 13th June to an online format.
Succeeding together in tomorrow’s dentistry – under this motto, Ivoclar Vivadent is inviting customers and partners to this year's International Expert Symposium, which will allow them to explore the opportunities and possibilities available for everyday work. In an online format, insight into the latest dental topics will be provided in an interactive and entertaining way: Participants can expect new, exciting impressions, inspiration, and interesting facts – presented by dental experts from all over the world.
“We’re convinced that this decision is the right path for us. As an innovative and reliable partner, we want to fulfil our philosophy and meet our customers’ needs in providing first-hand information about the latest trends and developments in the dental world, even in this challenging time. By hosting the IES 2020 as an online event, we are taking the current situation into consideration and at the same time providing our customers and partners with an attractive platform,” explains CEO Diego Gabathuler.
Oral care coverage acts as a strong draw for enrolling in Medicare Advantage plans, National Poll on Healthy Aging finds
Nearly all older Americans support adding a dental benefit to the Medicare program that covers most people over age 65, according to a new national poll that also reveals how often costs get in the way of oral health for older adults.
Ninety-three percent of people between the ages of 65 and 80 favor including dental coverage in traditional Medicare, though the percentage dropped to 59% when they were asked if they’d favor it even if they had to pay more for their Medicare benefits
Just over half of the older adults polled (53%) said they currently have dental coverage. Half of this group are covered as employees or retirees, or spouses of employees.
Another quarter said they have dental coverage because they’ve chosen to get their Medicare coverage through a Medicare Advantage plan offered by a commercial insurance company. In fact, 72% of those with Medicare Advantage coverage said they’d chosen their plan in part because it covered dental care.
Whether they had insurance or not, cost plays a role in dental decisions, the poll finds. One in five of the older adults polled said they had delayed getting dental care, or gone without it, in the past two years.
The majority of these respondents said cost, or insurance problems, played a role in this decision. Those without dental insurance, and those with lower incomes, were more likely to say they’d delayed or gone without oral care.
The new results come from the National Poll on Healthy Aging, carried out by the University of Michigan Institute for Healthcare Policy and Innovation with support from AARP and Michigan Medicine, U-M’s academic medical center. It involved a national sample of more than 1,030 adults aged 65 to 80 who answered a range of questions about their own oral health and dental health policy.
“These results suggest that health care providers and policymakers should seek solutions to better identify and address how cost and other factors act as barriers to dental care among older adults,” says Domenica Sweier, Ph.D., D.D.S.
Sweier, a clinical associate professor at the U-M School of Dentistry, helped develop the poll questions and analyze the results. She adds that as providers and policy makers continue to seek solutions, “This will be important to preventing health and social consequences of unmet oral health needs in this population.”
Differences across the over-50 age range
A previous National Poll on Healthy Aging report looked at dental health, including insurance and cost factors, among people in their 50s and early 60s. Only one in four of those polled said they lacked dental insurance, but half said they did not know how they would get dental coverage after they retired and some assumed that traditional Medicare would cover their dental care needs.
“Across the spectrum of ages, dental care and coverage vary, and cost plays a major role,” says Preeti Malani, M.D., director of the poll and a professor of internal medicine at U-M with special training in the care of older adults. “We know that poor oral health can affect everything from social interactions to eligibility for surgery, so it’s important for health professionals as well as policymakers to understand what older adults are experiencing.”
One in four of the adults over 65 polled (27%) said they were embarassed by the condition of the teeth, and about the same percentage rated their overall dental health as fair or poor.
The role of dental care costs
One in three hadn’t been to the dentist for preventive care such as a cleaning in at least a year. When the research team cross-referenced this with household income, they found that those with incomes over $60,000 were nearly twice as likely as those with incomes less than $30,000 to have gone to the dentist in the past year.
Nearly half of the poll sample (46%) said they were missing teeth but didn’t have a denture or implant to fill the gap.
“Coverage of dental care, as well as vision and hearing care, is critical for the long-term health of our population” says Alison Bryant, Ph.D., senior vice president of research for AARP. “Even simple teeth cleanings may not be affordable to seniors living on fixed incomes, so having coverage for dental benefits may help address that problem.”
The poll also shines additional light on the growing body of evidence linking oral health and overall health and wellbeing. Those who said their overall physical or mental health were fair or poor also visited the dentist’s office less often, and were more likely to say their oral health was poor. Problems with dry mouth related to medication use, and challenges eating a healthy diet because of untreated dental problems, could make these issue worse, says Malani.
The National Poll on Healthy Aging results are based on responses from a nationally representative sample of 1,039 adults aged 65 to 80 who answered a wide range of questions online. Questions were written, and data interpreted and compiled, by the IHPI team. Laptops and Internet access were provided to poll respondents who did not already have them.
A full report of the findings and methodology is available at www.healthyagingpoll.org, along with past National Poll on Healthy Aging reports.
Findings Have Implications for Studying Evolution of Menopause, Birth Patterns, and Offspring Rearing of Earlier Humans
Teeth constitute a permanent and faithful biological archive of the entirety of the individual’s life, from tooth formation to death, a team of researchers has found. Its work provides new evidence of the impact that events, such as reproduction and imprisonment, have on an organism.
“Our results make clear that the skeleton is not a static organ, but rather a dynamic one,” explains Paola Cerrito, a doctoral candidate in NYU’s Department of Anthropology and College of Dentistry and the lead author of the paper, which appears in the journal Scientific Reports.
The paper’s other authors include Shara Bailey, a professor in NYU’s Department of Anthropology, Bin Hu, an associate research scientist at NYU’s College of Dentistry, and Timothy Bromage, a professor at NYU’s College of Dentistry.
The research focused on cementum, the dental tissue that covers the tooth’s root. It begins to form annual layers—similar to a tree’s “rings”—from the time the tooth surfaces in the mouth.
“The discovery that intimate details of a person’s life are recorded in this little-studied tissue, promises to bring cementum straight into the center of many current debates concerning the evolution of human life history,” says Bromage.
The Scientific Reports study tested the hypothesis that physiologically impactful events—such as reproduction and menopause in females and incarceration and systemic illnesses in both males and females—leave permanent changes in the microstructure of cementum and that such changes can be accurately timed.
“The cementum’s microstructure, visible only through microscopic examination, can reveal the underlying organization of the fibers and particles that make up the material of this part of the tooth,” notes Cerrito, who obtained her bachelor’s degree at Sapienza University of Rome.
In their work, the scientists examined nearly 50 human teeth, aged 25 to 69, drawn from a skeletal collection with known medical history and lifestyle data, such as age, illnesses, and movement (e.g., from urban to rural environments). Much of this information was obtained from the subjects’ next of kin. They then used a series of imaging techniques that illuminated cementum bands, or rings, and linked each of these bands to different life stages, revealing connections between tooth formation and other occurrences.
“A tooth is not a static and dead portion of the skeleton,” observes Cerrito. “It continuously adjusts and responds to physiological processes.
“Just like tree rings, we can look at ‘tooth rings’: continuously growing layers of tissue on the dental root surface. These rings are a faithful archive of an individual's physiological experiences and stressors from pregnancies and illnesses to incarcerations and menopause that all leave a distinctive permanent mark.”
The research was supported by a grant from the National Science Foundation (BCS-1062680) as well as by a Max Planck Research Award.
The first study looking at the effect of chlorhexidine mouthwash on the entire oral microbiome has found its use significantly increases the abundance of lactate-producing bacteria that lower saliva pH, and may increase the risk of tooth damage.
A team led by Dr Raul Bescos from the University of Plymouth's Faculty of Health gave a placebo mouthwash to subjects for seven days, followed by seven days of a chlorhexidine mouthwash.
At the end of each period, the researchers carried out an analysis of the abundance and diversity of the bacteria in the mouth - the oral microbiome - as well as measuring pH, saliva buffering capacity (the ability to neutralise acids in the mouth), lactate, glucose, nitrate and nitrite concentrations.
The research, published in Scientific Reports today, found using chlorhexidine mouthwash over the seven days led to a greater abundance of species within the families of Firmicutes and Proteobacteria, and fewer Bacteroidetes, TM7 and Fusobacteria. This change was associated with an increase in acidity, seen in lower salivary pH and buffering capacity.
Overall, chlorhexidine was found to reduce microbial diversity in the mouth, although the authors cautioned more research was needed to determine if this reduction in diversity itself increased the risk of oral disease.
One of the primary roles of saliva is to maintain a neutral pH in the mouth, as acidity levels fluctuate as a result of eating and drinking. If saliva pH gets too low, damage can occur to the teeth and mucosa - tissue surrounding the teeth and on the inside of the mouth.
The research also confirmed findings from previous studies indicating that chlorhexidine disrupted the ability of oral bacteria to turn nitrate into nitrite, a key molecule for reducing blood pressure. Lower saliva and blood plasma nitrite concentrations were found after using chlorhexidine mouthwash, followed by a trend of increased systolic blood pressure. The findings supported earlier research led by the University that showed the blood pressure-lowering effect of exercise is significantly reduced when people rinse their mouths with antibacterial mouthwash rather than water.
Dr Bescos said: "There is a surprising lack of knowledge and literature behind the use of these products. Chlorhexidine mouthwash is widely used but research has been limited to its effect on a small number of bacteria linked to particular oral diseases, and most has been carried out in vitro.
"We believe this is the first study to look at the impact of 7-day use on the whole oral microbiome in human subjects."
Dr Zoe Brookes and Dr Louise Belfield, Lecturers in the Peninsula Dental School at the University of Plymouth, are co-authors of the study.
Dr Belfield said: "We have significantly underestimated the complexity of the oral microbiome and the importance of oral bacteria in the past. Traditionally the view has been that bacteria are bad and cause diseases. But we now know that the majority of bacteria - whether in the mouth or the gut - are essential for sustaining human health."
Dr Brookes added: "As dental clinicians, we need more information on how mouthwashes alter the balance of oral bacteria, so we can prescribe them correctly. This paper is an important first step in achieving this.
"In the face of the recent COVID-19 outbreak many dentists are now using chlorhexidine as a pre-rinse before doing dental procedures. We urgently need more information on how it works on viruses"
The study was carried out by a team from the University of Plymouth's Institute of Health and Community, Peninsula Dental School, Peninsula Medical School and School of Biological and Marine Sciences, along with colleagues from Bishop Grosseteste University and University of the West of Scotland.
Henry Schein, Inc. (Nasdaq: HSIC) announced today the availability of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, intended to be administered at the point of care. The test delivers results within 15 minutes from a pinprick with no instrumentation required.
Health care professionals can use the results of the test, along with a patient’s medical history, symptoms, and results of other relevant testing, to make informed decisions about patient treatment and care.
Henry Schein is working through multiple channels to distribute the tests in the United States as quickly as possible in response to the urgent need for rapid, accurate testing. The Company anticipates having at least several hundred thousand tests available by March 30 and significantly increased availability beginning in April 2020.
The Standard Q COVID-19 test is a rapid immunochromatography test designed for the qualitative presumptive detection of specific IgM and IgG antibodies associated with the 2019 novel coronavirus (SARS-CoV-2) in blood drawn with a pinprick.
Because serology tests measure antibodies, they can help assess the likelihood of past as well as present infection, and are meant to be used as an aid to health care professionals in diagnosing the mid- to later stages of the viral infection. Along with other information, such as the presence of symptoms, the tests may help health care professionals assess whether individuals (including health care workers) have recovered from the virus. Follow-up testing with a molecular diagnostic should be considered to confirm or rule out infection.
The Standard Q COVID-19 IgM/IgG Rapid Test is being made available under emergency guidance issued by the U.S. Food and Drug Administration (FDA).
“Henry Schein is committed to providing health care professionals with quality products they can rely on to care for patients,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Henry Schein has played a key role in providing point-of-care testing to health care professionals, and is now responding to the urgent need for wide availability of rapid point-of-care testing for COVID-19. This pandemic is an unprecedented situation, and making rapid diagnostic tools available to health care professionals is critical for detecting and mitigating the spread of the coronavirus.”
As the world’s largest distributor of health care solutions to office-based dental and medical professionals, Henry Schein is uniquely positioned to distribute the Standard Q COVID-19 test efficiently. Henry Schein plans to make the Standard Q COVID-19 test available for use by physician offices, hospitals, and other relevant health care institutions.
The distribution of the kit is part of Henry Schein’s continued efforts to address pandemic preparedness and response. Among other efforts, Henry Schein is in direct contact with the World Health Organization and other multilateral and domestic organizations as part of Henry Schein’s role as the private-sector lead of the Pandemic Supply Chain Network, a public-private partnership created in 2015 to improve the efficiency of the supply chain for personal protective equipment.
The Standard Q COVID-19 test is manufactured by SD Biosensor, Inc., a global bio-diagnostic company. SD BioSensor is represented by VelocityDX in the United States. Henry Schein intends to add other tests from VelocityDX and other suppliers specific to COVID-19, with the goal of offering a wide array of point-of-care tests for health care professionals.
A Q&A addressing the new test and providing additional information about it is available at www.henryschein.com/COVID19Statements.
For customers interested in more information about the Standard Q COVID-19 IgM/IgG Rapid Test, please contact Henry Schein at (844) 211-0140.
To learn more about what Henry Schein is doing to address this unprecedented situation and the actions the Company is taking to get more product into the hands of those who need it most – health care workers – please visit www.henryschein.com/COVID19update.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," “to be,” “to make,” “understand or understanding,” or other comparable terms. Forward looking statements include the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been independently verified under normal FDA procedures. A full discussion of our operations and financial condition, status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; increased competition by third party online commerce sites; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; risks associated with the Novel Coronavirus Disease 2019 (COVID-19); risk associated with the United Kingdom's withdrawal from the European Union; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; litigation risks; new or unanticipated litigation developments and the status of litigation matters; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Seeing is believing: imaging and visualization capabilities of the iTero Element 5D Imaging System are designed to enable better patient engagement and lead to increased patient acceptance of recommended dental treatment
• First intraoral scanner with near-infrared imaging (NIRI) technology that scans the internal structure of a tooth (enamel and dentin) in real time1.
• First integrated dental imaging system that records 3D, intra-oral color and NIRI with a single scan, and enables comparison over time using iTero® TimeLapse1.
• NIRI technology of the iTero Element® 5D system aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation1.
Commenting on today’s announcement,
iTero Element 5D Imaging System: better clinical care
The iTero Element 5D scanner is the first integrated dental imaging system that simultaneously records 3D, intra-oral color and NIRI images and enables comparison over time using iTero TimeLapse1. Integrated 3D, intra-oral color and NIRI technology of the iTero Element 5D Imaging System aids doctors in detecting and monitoring the progression of interproximal caries (cavities or tooth decay) above the gingiva without using harmful radiation1, thereby helping to ensure that their patients receive even better care with visualization, education, and treatment acceptance.
The diagnosis of carious lesions or “caries,” especially interproximal lesions or those between teeth, can be hampered by several factors, including variations in the shape and alignment of teeth, traditional limitations of X-ray examinations that include variability in exposure level, bad angulations in the captured image, or overlapping contacts in the image, among other factors. With the iTero Element 5D Imaging System, doctors can scan patients at each visit to view a patient’s progress over time and together view treatment options that result in clearer decisions for better clinical care.
A survey of doctors outside of the
More than just a scanner
With one full arch scan, completed in as little as 60 seconds2, the iTero Element 5D Imaging System provides doctors with powerful visualization capabilities, including:
• NIRI (near infrared image)
• Intraoral camera
• 3D impressions for restorative and orthodontic work
• Analysis instruments, such as the Occlusogram occlusal clearance tool
• iTero TimeLapse technology
• Invisalign® Outcome Simulator and Progress Assessment
The iTero Element 5D Imaging System will be commercially available in
¹Data on file at
2Data on file at
Information about the iTero Element 5D Imaging System can be found at http://www.itero.com/en/products/itero_element_5d.
For a complete list of
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com.
For additional information about iTero digital scanning system, please visit www.itero.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements regarding the capabilities and performance of Align’s products, the timing of their availability including as a result of the COVID-19 pandemic. These forward-looking statements are based on current expectations and estimates and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to the risk factors under the heading “Risk Factors” in the company’s annual report on Form 10-K for the year ended December 31, 2019, as updated by the company’s other filings with the Securities and Exchange Commission. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Align undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Zest Dental Solutions, the only manufacturer of the Zest LOCATOR® Family of Attachment Systems, provider of clinician trusted dental materials and small equipment, enters the digital workflow with the launch of abutment level Scan Bodies for LOCATOR®.
The Scan Body for the Zest LOCATOR Attachment System was designed to automatically create the exact dimension and undercut required to retain the LOCATOR denture attachment housing within a 3D printed or milled prosthesis. The precise location of the LOCATOR and implant are captured through the scan, either intraorally or in a lab setting, for easy case planning and design. The overdenture is then 3D Printed or milled with the recess for the LOCATOR housing, allowing for easy, and quicker pick-up.
“At Zest, we are always striving to deliver products and solutions that help clinicians practice smarter and provide better dentistry resulting in happy patients,” says Tom Stratton, CEO Zest Dental Solutions. “By bringing LOCATOR into the digital workflow, clinicians can save time while improving the accuracy and consistency of their overdenture cases.”
The LOCATOR Scan Bodies are made of a durable PEEK material which can be sterilized and reused. They are available for all LOCATOR Attachments Systems, including LOCATOR Root, LOCATOR abutments and LOCATOR abutments for LOCATOR Implants.
About Zest Dental Solutions
Zest Dental Solutions is a global leader in the design, development, manufacturing and distribution of diversified dental solutions for a continuum of patient care from the preservation of natural teeth to the treatment of total edentulism. The company's product offering consists of a range of solutions including the LOCATOR® Family of Attachment Systems, LOCATOR Implant Systems, Consumables and Dental Equipment, with global distribution through Implant Companies, dealer/distributor networks, as well as a domestic retail sales operation. Zest Dental Solutions is headquartered in Carlsbad, California with operations in Anaheim and Escondido, California. Zest Dental Solutions is a portfolio company of BC Partners, a leading private equity firm. For more information, please visit www.zestdent.com